Therefore, our findings open up opportunities for targeting (the) interaction(s) responsible for ASK1 activation towards developing selective ASK1 signaling inhibitors and ultimately pharmaceutical drugs for several inflammatory, cardiovascular, and neurodegenerative diseases, among others (Budas et al., 2018; Ogier et al., 2020). This evidence concerns the gene MAP3K5 and neurodegenerative disease.